Pharmacotherapy for Nocturia
Andersson, Karl Erik LU
and Van Kerrebroeck, Philip
(2018)
In Current Urology Reports
19(1).
- Abstract
PURPOSE OF REVIEW: To assess current pharmacological principles used for treatment of nocturia/nocturnal polyuria.
RECENT FINDINGS: The pathophysiology of nocturia is often multifactorial, but two main mechanisms have been identified, occurring alone or in combination: low functional bladder capacity and nocturnal polyuria. The multifactorial pathophysiology not only implies several possible targets for therapeutic intervention but also means that it is unlikely that one treatment modality including drugs will be successful in all patients. Drugs approved for the treatment of male LUTS and male and female OAB are known to be far more effective for treatment of the daytime symptoms than for nocturia. Several pharmacological... (More)
PURPOSE OF REVIEW: To assess current pharmacological principles used for treatment of nocturia/nocturnal polyuria.
RECENT FINDINGS: The pathophysiology of nocturia is often multifactorial, but two main mechanisms have been identified, occurring alone or in combination: low functional bladder capacity and nocturnal polyuria. The multifactorial pathophysiology not only implies several possible targets for therapeutic intervention but also means that it is unlikely that one treatment modality including drugs will be successful in all patients. Drugs approved for the treatment of male LUTS and male and female OAB are known to be far more effective for treatment of the daytime symptoms than for nocturia. Several pharmacological principles have been tested with varying success. The treatment of choice should depend upon the main underlying cause, thus aiming primarily to increase bladder capacity by counteracting detrusor overactivity and/or reducing nocturnal polyuria. Using current available agents, effective, personalized treatment should be designed taking into account gender, co-morbidities, and identified etiological factors. However, there is a medical need for new, approved drugs for treatments for patients with nocturia.
(Less)
- author
- Andersson, Karl Erik
LU
and Van Kerrebroeck, Philip
- organization
- publishing date
- 2018-02-09
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Global polyuria, Nocturnal polyuria, Overactive bladder, Pharmacological principles, Reduced bladder capacity
- in
- Current Urology Reports
- volume
- 19
- issue
- 1
- pages
- 1 pages
- publisher
- Current Medicine Group
- external identifiers
-
- scopus:85049246275
- pmid:29427214
- ISSN
- 1527-2737
- DOI
- 10.1007/s11934-018-0750-y
- language
- English
- LU publication?
- yes
- id
- 1b9d59a9-15b3-4051-9d66-daab56319e99
- date added to LUP
- 2018-07-17 10:58:14
- date last changed
- 2024-06-24 17:01:41
@article{1b9d59a9-15b3-4051-9d66-daab56319e99,
abstract = {{<p>PURPOSE OF REVIEW: To assess current pharmacological principles used for treatment of nocturia/nocturnal polyuria.</p><p>RECENT FINDINGS: The pathophysiology of nocturia is often multifactorial, but two main mechanisms have been identified, occurring alone or in combination: low functional bladder capacity and nocturnal polyuria. The multifactorial pathophysiology not only implies several possible targets for therapeutic intervention but also means that it is unlikely that one treatment modality including drugs will be successful in all patients. Drugs approved for the treatment of male LUTS and male and female OAB are known to be far more effective for treatment of the daytime symptoms than for nocturia. Several pharmacological principles have been tested with varying success. The treatment of choice should depend upon the main underlying cause, thus aiming primarily to increase bladder capacity by counteracting detrusor overactivity and/or reducing nocturnal polyuria. Using current available agents, effective, personalized treatment should be designed taking into account gender, co-morbidities, and identified etiological factors. However, there is a medical need for new, approved drugs for treatments for patients with nocturia.</p>}},
author = {{Andersson, Karl Erik and Van Kerrebroeck, Philip}},
issn = {{1527-2737}},
keywords = {{Global polyuria; Nocturnal polyuria; Overactive bladder; Pharmacological principles; Reduced bladder capacity}},
language = {{eng}},
month = {{02}},
number = {{1}},
publisher = {{Current Medicine Group}},
series = {{Current Urology Reports}},
title = {{Pharmacotherapy for Nocturia}},
url = {{http://dx.doi.org/10.1007/s11934-018-0750-y}},
doi = {{10.1007/s11934-018-0750-y}},
volume = {{19}},
year = {{2018}},
}